PharmaTher Holdings Ltd AI Stock Analysis
Want to see TSE:PHRM full AI Analyst Report?
PharmaTher Holdings Ltd (PHRM) AI Stock Analysis
PharmaTher Holdings Ltd
(CNQX:PHRM)
The score is held back primarily by weak financial fundamentals typical of a pre-revenue biotech (ongoing losses/cash burn and sharply reduced equity), despite the benefit of having no debt and improving loss/cash-burn trends. Technicals are comparatively supportive with price above major short/medium moving averages and positive momentum, while valuation is constrained by negative earnings and no dividend.
PharmaTher Holdings Ltd (PHRM) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 3.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 58.35K
- Price to Earnings (P/E)
- -11.9
- Beta (1Y)
- -0.16
- Revenue Growth
- ―
- EPS Growth
- 75.84%
- Country
- Canada
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PharmaTher Holdings Ltd Business Overview & Revenue Model
Company Description
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techni...
PharmaTher Holdings Ltd Financial Statement Overview
Summary
Overall financials reflect an early-stage, pre-revenue biotech: revenue is 0 and profitability remains negative. Positives include no debt, materially narrowing net losses (from about -6.4M in 2023 to about -0.6M in 2026), and reduced operating cash burn in 2026 versus 2024–2025. Key risks are persistent negative operating cash flow/free cash flow and a steep erosion of equity (about 11.8M in 2022 to about 0.6M in 2026), which limits financial flexibility.
Income Statement
12Very NegativeBalance Sheet
38NegativeCash Flow
18Very Negative| Breakdown | TTM | Aug 2026 | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -711 | -1,422 | -1,777 |
| EBITDA | -845.95K | -845.95K | -1.52M | -3.04M | -3.96M | -3.96M |
| Net Income | -610.44K | -610.44K | -1.53M | -3.12M | -6.42M | -4.01M |
Balance Sheet | ||||||
| Total Assets | 1.12M | 1.12M | 1.34M | 2.59M | 6.31M | 12.16M |
| Cash, Cash Equivalents and Short-Term Investments | 921.54K | 921.54K | 1.12M | 2.30M | 6.25M | 12.12M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 509.14K | 509.14K | 366.33K | 252.90K | 892.48K | 330.32K |
| Stockholders Equity | 613.11K | 613.11K | 973.54K | 2.34M | 5.42M | 11.83M |
Cash Flow | ||||||
| Free Cash Flow | -485.00K | -485.01K | -1.21M | -3.52M | -3.24M | -3.51M |
| Operating Cash Flow | -485.01K | -485.01K | -1.21M | -3.52M | -3.24M | -3.51M |
| Investing Cash Flow | 0 | 0 | 0 | -300.00K | 0 | 0 |
| Financing Cash Flow | 250.00K | 250.00K | 0 | 35.00K | 0 | 9.89M |
PharmaTher Holdings Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRM, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.82 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRM.
PharmaTher Holdings Ltd Peers Comparison
Overall Rating
- TSE:PHRM50Neutral
TSE:MRVL46Neutral
TSE:BETR41Neutral
TSE:KNE40Underperform
TSE:CSCI34Underperform
TSE:BIOV28.5Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:PHRM | 50Neutral | CAD 4.55M | -11.90 | -75.59% | ― | ― | 75.84% |
| TSE:MRVL | 46Neutral | CAD 7.56M | -4.87 | 39.05% | ― | ― | 25.70% |
| TSE:BETR | 41Neutral | CAD 117.42M | -9.32 | 34.90% | ― | ― | -266.67% |
| TSE:KNE | 40Underperform | CAD 6.15M | -2.05 | 273.53% | ― | ― | ― |
| TSE:CSCI | 34Underperform | CAD 8.37M | -0.46 | -48.52% | ― | -13.00% | 75.31% |
| TSE:BIOV | 29Underperform | CAD 2.04M | -0.35 | 149.46% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:PHRM | PharmaTher Holdings Ltd | 0.05 | -0.10 | -66.67% | |
| TSE:CSCI | Cosciens Biopharma Inc. | 8.52 | -1.38 | -13.94% | |
| TSE:KNE | Kane Biotech | 0.03 | -0.01 | -25.00% | |
| TSE:BETR | Betterlife Pharma Inc. | 0.19 | 0.13 | 216.67% | |
| TSE:BIOV | Biovaxys Technology Corp | 0.07 | -0.19 | -73.08% | |
| TSE:MRVL | Marvel Biosciences Corp | 0.12 | -0.06 | -36.11% |
PharmaTher Holdings Ltd Corporate Events
PharmaTher Targets New U.S. Peptide Pathway With 3D-Printed Colon-Directed KPV and BPC-157
PositivePharmaTher is expanding its M3DICINES 3D-printing platform into a portfolio of personalized peptide products for niche indications, initially centering on oral, colon-targeted KPV and BPC-157 enabled by Craft Health’s CORR3CT technology. The company...
PharmaTher Seeks FDA Special Designations for 3D-Printed Creatine in Rare Pediatric GAMT Disorder
PositivePharmaTher has submitted applications to the FDA for Orphan Drug Designation and Rare Pediatric Disease Designation for a 3D-printed creatine monohydrate product to treat guanidinoacetate methyltransferase deficiency, a severe inherited pediatric dis...
PharmaTher Secures Exclusive North American Rights to Craft Health’s 3D Pharma Printing Platform
PositivePharmaTher has signed an exclusive distribution agreement with Singapore-based Craft Health to distribute its CraftMake pharmaceutical 3D printing platform, software, printable formulations and consumables across North America. The deal positions Pha...
PharmaTher Taps PD Labs as U.S. Hub for 3D-Printed Personalized Medicines
PositivePharmaTher has advanced the commercialization of its PERSONALIZ3D platform by selecting PD Labs, a national 503A compounding pharmacy in Texas, as its U.S. Center of Excellence. The move marks completion of the first stage of its three-part plan to i...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 06, 2026